Epizyme, Inc.
Clinical trials sponsored by Epizyme, Inc., explained in plain language.
-
New hope for hard-to-treat lymphoma: experimental combo aims to keep cancer at bay
Disease control OngoingThis study tests whether adding the experimental drug tazemetostat to a standard two-drug therapy can help people with relapsed or refractory follicular lymphoma live longer without their cancer getting worse. About 555 adults whose lymphoma has returned or no longer responds to …
Phase: PHASE3 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New hope for lymphoma patients: study tests targeted pill for Tough-to-Treat cancers
Disease control TerminatedThis study looked at how well and how safely the drug tazemetostat works in adults with a type of blood cancer called follicular lymphoma that has come back or not responded to previous treatments. Participants took tazemetostat pills twice daily. The study aimed to see if the dr…
Phase: PHASE2 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated May 18, 2026 11:59 UTC